All KOL Pulse conferences
Post-Conference Intelligence · Oct 17 – Oct 21, 2025

ESMO 2025

Berlin, DE — top KOL voices, trial buzz, and themes pulled from verified physician social.
555Physician tweets
189Unique KOLs
1.5MTotal impressions
KOL Voices

Who moved the needle at ESMO 2025

Top physician voices ranked by impressions. Institutional / media accounts excluded.

Emerging Themes

What KOLs were talking about

Click any theme to see the top tweets that matched.

Paolo Tarantino
@ptarantinomd
DB-11 abstract just released. In high-risk (≥T3, N+, or IBC) HER2+ eBC, neoadjuvant T-DXd-THP outperformed ddAC-THP (pCR rate 67% vs 56%, p=0.003), with reduction in cardiotoxicity (LVD 1.9 vs 9%) and low rate of ILD (4.4 vs 5.1%). The last nail in the coffin for anthracyclines.
22.6K impressions
Mustafa Özdoğan, MD
@ozdogan_md
Paradigm Shift in 1L TNBC We may be witnessing the end of chemotherapy’s monopoly in PD-L1–negative metastatic TNBC. Dato-DXd delivers the first OS benefit in this setting. SG shows a robust PFS advantage and prolonged DOR ≈ 12 mo. Next frontier → sequencing & chemo-free https://t.co/khXfHoUXaH
18.3K impressions
Yakup Ergün
@dr_yakupergun
#ESMO25 DESTINY-Breast11-Positive✅ but Current standard: 6× THP or TCbHP, already short & anthracycline-free. pCR ↑ 11% is notable — but if residual disease remains, then what? Will we give T-DM1, which is weaker than T-DXd? Or extrapolate from DB-05 and use adjuvant T-DXd https://t.co/uWP1Gelo3H https://t.co/JzbSLH8K0O
9.7K impressions
Elisa Agostinetto
@elisaagostinett
At #ESMO25 Ana Garrido-Castro discusses results of ASCENT-03 and TROPION-Breast02 🔸Crossover was allowed in Ascent, but not in TB02, potentially impacting OS 🔸Pts with more aggressive disease included in TB02 ➡️choice to be guided by safety profile of each ADC? @OncoAlert https://t.co/e82Fnt2D3u
9.2K impressions
Elisabetta Bonzano MD, PhD
@to_be_elizabeth
📌 ✨DESTINY-Breast11✨ Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel + trastuzumab + pertuzumab vs SOC for high-risk HER2+ early breast cancer @Prof_Nadia_H Presidential Symposium #ESMO25 @OncoAlert #OncoAlertAF https://t.co/Kn5FkVro6O
7.0K impressions
Dr Amol Akhade
@suyogcancer
Tdxd alone was not effective as NACT . I am surprised. Are u ? #destinybreast11 @dr_yakupergun @ErikaHamilton9 @myESMO https://t.co/Sz3H5IEDgH
7.0K impressions
Paolo Tarantino
@ptarantinomd
DB-11 abstract just released. In high-risk (≥T3, N+, or IBC) HER2+ eBC, neoadjuvant T-DXd-THP outperformed ddAC-THP (pCR rate 67% vs 56%, p=0.003), with reduction in cardiotoxicity (LVD 1.9 vs 9%) and low rate of ILD (4.4 vs 5.1%). The last nail in the coffin for anthracyclines.
22.6K impressions
Oncology Brothers
@oncbrothers
Day 1 #ESMO25 Highlights: Breast Ca: 1. #POSITIVE 🤰 outcomes 2. #monarchE HR+ Adj Abema 3. #NATALEE HR+ Adj Ribo Lung Ca: 4. #NorthStar Local Rx in mEGFR 5. #FLAURA2 Chemo + Osi in mEGFR 6. #SOHO01 & #BeamionLung01
19.6K impressions
Yakup Ergün
@dr_yakupergun
Ask any breast oncologist today, and they’ll tell you they prefer anthracycline-free regimens in HER2-positive breast cancer — and that anthracyclines don’t improve response rates. So how did we accept a control arm containing anthracyclines in the DESTINY-Breast11 trial, which https://t.co/1YqiufBb3t
16.3K impressions
Mustafa Özdoğan, MD
@ozdogan_md
A standing ovation moment at #ESMO25 In front of more than 9,000 cancer specialists and researchers, the Phase 3 RC48-C016 trial redefined the outlook for HER2-expressing urothelial cancer: Disitamab vedotin + Toripalimab nearly doubled overall survival over chemotherapy — https://t.co/F3csWdJDES
11.4K impressions
NEJM
@nejm
Original Article: Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer (SOHO-01 phase 1–2 study) https://t.co/j9U1z5qZAS #ESMO25 | @myESMO https://t.co/2ARAQUTjOd
10.5K impressions
Yakup Ergün
@dr_yakupergun
#ESMO25 Managing HR+/HER2– mBC in 2025 💬An update is likely following the evERA and VIKTORIA-1 trials From Dr. William Gradishar's presentation👇 https://t.co/noV6ro3VPZ
9.7K impressions
Nicholas Hornstein
@gimedonc
Holy smokes, MATTERHORN hits OS! 🏔️🔥 We’ve been waiting for this one. After FLOT became standard for resectable gastric and GEJ adenocarcinoma, everyone wondered if adding immunotherapy could move the bar. Earlier this year, MATTERHORN showed a big EFS win for DFLOT, along with
28.0K impressions
Mustafa Özdoğan, MD
@ozdogan_md
Paradigm Shift in 1L TNBC We may be witnessing the end of chemotherapy’s monopoly in PD-L1–negative metastatic TNBC. Dato-DXd delivers the first OS benefit in this setting. SG shows a robust PFS advantage and prolonged DOR ≈ 12 mo. Next frontier → sequencing & chemo-free https://t.co/khXfHoUXaH
18.3K impressions
The Lancet
@thelancet
HARMONi-6: In patients with untreated advanced squamous NSCLC, ivonescimab plus chemotherapy showed significantly improved progression-free survival compared with tislelizumab plus chemotherapy, regardless of PD-L1 status. https://t.co/C6kHHPmbLa #ESMO25
15.8K impressions
Joe Y Chang
@joechangmd
PD-1 >=50% is a very strong indicator for immunotherapy. No chemo needed is confirmed. https://t.co/5mFerSlQvq
11.3K impressions
Stephen V Liu, MD
@stephenvliu
#ESMO25 Dr. @Ilias_Houda presents randomized phase III PAULIEN trial of 1L pembro vs chemo + pembro in PD-L1 high NSCLC. Only 72 patients, as study stopped early for futility. #ESMOAmbassadors https://t.co/N4CMZwQc6s
11.0K impressions
Yüksel Ürün
@dryukselurun
Ivonescimab + chemo improved PFS over tislelizumab + chemo (11.1 vs 6.9 mo, HR 0.60, p<0.0001) in 1L sq-NSCLC. Benefit seen across PD-L1 groups. Dual target strategy keeps moving, VEGF still matters. #ESMO25 @TeresaSAmaral @E_de_Azambuja @JyotiBajpai01 @ArBayle https://t.co/HyqvIC1aJU
6.8K impressions
Yüksel Ürün
@dryukselurun
In muscle-invasive bladder cancer, ctDNA-guided adjuvant atezolizumab improved disease-free and overall survival. Proud to be part of this work, with @tompowles1 and all colleagues, patients, families, and sponsors who made it real. @NEJM @myESMO #ESMO25 @OncoBellmunt https://t.co/vMHzuvKxKK
9.3K impressions
NEJM
@nejm
Original Article: ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer (IMvigor011 phase 3 trial) https://t.co/8DupP4lavg #ESMO25 | @myESMO https://t.co/Ag2IqoXUyE
8.7K impressions
Mario Balsa
@mariobalsamd
💎 #ESMO25 Presidential Session w/ @JeanneTie #ColorectalCancer – Phase III DYNAMIC-III: ctDNA-guided de-escalation after surgery in stage III colon cancer In ctDNA⁻ patients: ☄️ 3-year RFS 85.3% vs 88.1% (standard) 🎯 Oxaliplatin exposure reduced 88.6% ➜ 34.8% 💥 Fewer https://t.co/4V5OLJ8Xbd
8.5K impressions
Neeraj Agarwal, MD, FASCO
@neerajaiims
Wonderful talk by @PGrivasMDPhD on neoadj #bladdercancer treatment w updates #NIAGARA , role of ctDNA and ongoing neoadjuvant/adjuvant trials👉his take home message for our clinical practice. #ESMO25 #ESMOAmbassador @OncoAlert @myESMO https://t.co/C1dfwHcn2w
6.5K impressions
Arndt Vogel
@arndtvogel
PARERE trial: Panitumumab retreatment followed by regorafenib vs the reverse sequence in chemorefractory mCRC with RAS/ BRAF WT ctDNA #ESMO25 #ESMOAmbassadors 👉 mOS: 11.6 vs 11.7mo 👉Better PFS for pani in both arms 🧐negative trial, but rechallenge is an option in 4L @myesmo https://t.co/N49WIEuuBv
4.8K impressions
Petros Grivas
@pgrivasmdphd
Indeed phenomenal broad impact by our friend @tompowles1 including excellent presentation @myESMO #ESMO25 evaluating the clinical utility of ctDNA in IO-naive pts with MIBC in adjuvant setting: IMvigor011 validated hypothesis generated by IMvigor010: https://t.co/lJZnZZ2Id2 https://t.co/We64H1559h https://t.co/VKMz3PfLCc
3.8K impressions
The Lancet
@thelancet
HARMONi-6: In patients with untreated advanced squamous NSCLC, ivonescimab plus chemotherapy showed significantly improved progression-free survival compared with tislelizumab plus chemotherapy, regardless of PD-L1 status. https://t.co/C6kHHPmbLa #ESMO25
15.8K impressions
Yüksel Ürün
@dryukselurun
Ivonescimab + chemo improved PFS over tislelizumab + chemo (11.1 vs 6.9 mo, HR 0.60, p<0.0001) in 1L sq-NSCLC. Benefit seen across PD-L1 groups. Dual target strategy keeps moving, VEGF still matters. #ESMO25 @TeresaSAmaral @E_de_Azambuja @JyotiBajpai01 @ArBayle https://t.co/HyqvIC1aJU
6.8K impressions
Stephen V Liu, MD
@stephenvliu
Dr. Shun Lu delivers HARMONi-6 results at #ESMO25: first line ivonescimab + chemotherapy vs tislelizumab (PD-1, approved by China, EMA) + chemo for advanced squamous NSCLC. Chemotherapy + immunotherapy is our standard of care but squamous outcomes remain poor. #ESMOAmbassadors https://t.co/xCInIye331
4.5K impressions
FiercePharma
@fiercepharma
Akeso and Summit Tx's ivonescimab and chemo reduced the risk of progression or death by 40% compared with BeOne’s Tevimbra and chemo in Chinese patients with first-line squamous NSCLC, according to HARMONi-6 data at #ESMO25 https://t.co/pEktPnQBS5
4.2K impressions
Rami Manochakian MD, FASCO Can
@rmanochakian
🔥🚨@OncoAlert Hot Off The Press. Just published @TheLancet in conjunction with presentation @myESMO #ESMO25 Results of: 🎯#HARMONi-6 phase 3 trial of: ⭐️#Ivonescimab + #Chemotherapy VS #Tislelizumab + #Chemotherapy as 1st line T…
3.7K impressions
Mustafa Özdoğan, MD
@ozdogan_md
Dual-Target Breakthrough in Lung Cancer At #ESMO25, the Phase 3 HARMONi-6 trial showed that ivonescimab (PD-1 × VEGF) + chemotherapy significantly improved PFS compared with PD-1 + chemo. Although OS data are still immature, the striking PFS advantage signals that this https://t.co/RUX2ESyxJM
3.5K impressions
Top Tweets

The 10 tweets that defined ESMO 2025

Physician voices only, ranked by impressions. Click any card to open the original on X.

Tom Powles
@tompowles1
#1
1/2 KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much ⬆️ than anything before #ESMO25 pCR> 50% questions unselected surgery https://t.co/DJQrlfKVFR
29.6K impressions
Nicholas Hornstein
@gimedonc
#2
Holy smokes, MATTERHORN hits OS! 🏔️🔥 We’ve been waiting for this one. After FLOT became standard for resectable gastric and GEJ adenocarcinoma, everyone wondered if adding immunotherapy could move the bar. Earlier this year, MATTERHORN showed a big EFS win for DFLOT, along with
28.0K impressions
Oncology Brothers
@oncbrothers
#3
~2 wks to #ESMO25! Here’s a📝of🔑studies for GeneralOnc that could change/reinforce SoC: - #DESTINYBreast 05&11 - #monarchE & #NATALEE - #VIKTORIA1 - #FORTITUDE01 - #DYNAMIC3 - #STELLAR303 - #KN905 …
25.4K impressions
Harold J. Burstein, MD, PhD, F
@drhburstein
#4
Important data from monarchE and NATALEE adjuvant CDK46 inhibitor @myESMO With @tess_omeara, here's our take on who needs, and who does not need, adjuvant abema/ribo, co-published in @Annals_Oncology https://t.co/ofrZzrsTqF
23.7K impressions
Paolo Tarantino
@ptarantinomd
#5
DB-11 abstract just released. In high-risk (≥T3, N+, or IBC) HER2+ eBC, neoadjuvant T-DXd-THP outperformed ddAC-THP (pCR rate 67% vs 56%, p=0.003), with reduction in cardiotoxicity (LVD 1.9 vs 9%) and low rate of ILD (4.4 vs 5.1%). The last nail in the coffin for anthracyclines.
22.6K impressions
Oncology Brothers
@oncbrothers
#6
We now have more data on adj CDK4/6i at #ESMO25 + we’ll continue to use these Rx in metastatic settings as well. This is the table we’ve used (AEs + doses) for #Ribociclib #Abemaciclib, + #Palbociclib w/ @DrSGraff for our #ToxCheck 🗣️ #bcsm
21.7K impressions
Stephen V Liu, MD
@stephenvliu
#7
Impressive results from MDT-BRIDGE at #ESMO25 from Dr. @MartinReck2. Pts with resectable or borderline had 2 cycles of durvalumab + chemo then reassessed at MDT. If resectable at start, 95% remained resectable. If borderline, 82% were then felt to be resectable. #ESMOAmbassadors https://t.co/5znQpW2J8o
21.6K impressions
Oncology Brothers
@oncbrothers
#8
Day 1 #ESMO25 Highlights: Breast Ca: 1. #POSITIVE 🤰 outcomes 2. #monarchE HR+ Adj Abema 3. #NATALEE HR+ Adj Ribo Lung Ca: 4. #NorthStar Local Rx in mEGFR 5. #FLAURA2 Chemo + Osi in mEGFR 6. #SOHO01 & #BeamionLung01
19.6K impressions
Toni Choueiri, MD
@drchoueiri
#9
Tom is changing bladder cancer SOC, one @myESMO and @ASCO meetings (twice/year) ….with concomitant @NEJM publications! No surprise that Pr. @tompowles1 is Top 10 @Nature people ! https://t.co/WnJSs8e9eN https://t.co/IRFE4L43jE
18.5K impressions
Mustafa Özdoğan, MD
@ozdogan_md
#10
Paradigm Shift in 1L TNBC We may be witnessing the end of chemotherapy’s monopoly in PD-L1–negative metastatic TNBC. Dato-DXd delivers the first OS benefit in this setting. SG shows a robust PFS advantage and prolonged DOR ≈ 12 mo. Next frontier → sequencing & chemo-free https://t.co/khXfHoUXaH
18.3K impressions
← Back to all conferences